Financial Data and Key Metrics Changes - The company reported a revenue increase of 12% year-over-year in Q4 2023, reaching $156 million, driven by growth in clinical test volume and improved revenue per test [10][27] - Adjusted gross profit increased by 17.8% year-over-year, with an adjusted gross margin of 46.7%, reflecting a 225 basis point improvement compared to Q4 2022 [8][34] - Adjusted EBITDA was positive at $9 million, marking a 900% improvement from the prior year [8][11] Business Line Data and Key Metrics Changes - Clinical Services revenue rose by 20% year-over-year to $130 million, supported by a 13% increase in revenue per test and a 6% increase in volume [4][27] - Advanced Diagnostics revenue declined by 17% year-over-year to $26 million in Q4, although it was up 5% sequentially [6][28] - The NGS (Next-Generation Sequencing) segment grew over 40% and now represents over 25% of total clinical revenue [5][28] Market Data and Key Metrics Changes - The company experienced strong growth in the community oncology market, contributing to overall revenue growth [35] - The average revenue per clinical test increased by 13% to $4.41, marking the 11th consecutive quarter of improvement [5][11] Company Strategy and Development Direction - The company aims to become the leading cancer testing information and decision support company, focusing on sustainable long-term growth [1] - Strategic priorities include profitably growing the core business, accelerating advanced diagnostics, and enhancing company culture [36] - The company is investing in digital transformation through a consolidated LIMS system to improve operational efficiency [40][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue growth target of 10% to 12% for 2024, with adjusted EBITDA expected to grow significantly [55][48] - The company is focused on addressing macroeconomic challenges and optimizing margins through strategic initiatives [6][28] - Management highlighted the importance of customer experience and operational efficiency as key drivers for future growth [141][143] Other Important Information - The company ended Q4 2023 with cash and marketable securities of $415 million, reflecting strong cash flow management [12][53] - The company is actively pursuing litigation related to MRD testing, emphasizing its commitment to serving cancer patients [45][129] Q&A Session All Questions and Answers Question: What is the company's strategy regarding FDA regulations and LDT? - Management indicated that they have been preparing for potential FDA rulings by enhancing their quality systems and ensuring compliance with regulatory standards [63][70] Question: Can you elaborate on the clinical volume growth expectations? - Management noted that they expect clinical volume growth to be driven by a mix of factors including NGS adoption and improved revenue cycle management [67][99] Question: How does the company plan to balance growth and profitability? - Management emphasized the importance of investing in growth initiatives while maintaining a focus on profitability, aiming for a balanced approach [85][106] Question: What are the expectations for the pharma services business? - Management sees significant growth opportunities in pharma services and informatics, with plans to expand the sales force in these areas [108][110] Question: How will the LIMS project impact operational efficiency? - The LIMS project is expected to enhance operational efficiency and productivity, leading to improved margins and turnaround times [92][94]

Financial Performance - Consolidated revenue increased by 16.1% compared to 2022, with Clinical Services revenue up 18.4% and Advanced Diagnostics Services revenue up 5.5%[240] - Total net revenue for 2023 increased by $81.9 million, or 16.1%, to $591.6 million compared to 2022[264] - Clinical Services revenue rose by $76.9 million, or 18.4%, to $495.6 million in 2023, driven by increased test volume and a favorable test mix[264] - Advanced Diagnostics revenue increased by $5.0 million, or 5.5%, to $96.0 million in 2023, primarily due to higher billings across its portfolio[265] - The net loss for the year ended December 31, 2023, was $87.968 million, a decrease from a net loss of $144.250 million in 2022, representing a 39% improvement[285] - Basic and diluted net loss per share for 2023 was $0.70, compared to $1.16 in 2022, indicating a 40% reduction in loss per share[285] - Non-GAAP Adjusted EBITDA for 2023 was $3.486 million, a significant recovery from a loss of $48.010 million in 2022[290] - The company reported a comprehensive loss of $85.743 million for 2023, compared to a comprehensive loss of $147.511 million in 2022[325] Operational Efficiency - Net cash used in operations improved by $64.0 million compared to 2022[240] - Adjusted EBITDA increased by $51.5 million to a positive $3.5 million compared to 2022[240] - Gross margin improved by 448 basis points while also enhancing turnaround time[240] - General and administrative expenses decreased by $0.3 million in 2023, representing 41.1% of revenue compared to 47.7% in 2022[271] - Research and development expenses decreased by $3.0 million in 2023, accounting for 4.6% of revenue, with expectations for future increases as new tests are developed[273][274] - Sales and marketing expenses increased by $3.5 million, or 5.2%, in 2023, primarily due to higher compensation and benefit costs[275] - Restructuring charges rose by $6.6 million, or 145.5%, in 2023, totaling $11.1 million, as part of a program to improve operational efficiency[277][279] Cash Flow and Liquidity - Cash used in operating activities decreased to $1.953 million in 2023 from $65.993 million in 2022, reflecting a $64.040 million improvement[291] - Cash provided by investing activities was $76.707 million in 2023, a substantial increase from cash used of $0.517 million in 2022[292] - Cash provided by financing activities decreased to $4.554 million in 2023 from $11.829 million in 2022, primarily due to a reduction in cash from stock issuance[293] - As of December 31, 2023, the company had $342.488 million in cash and cash equivalents, up from $263.180 million at the end of 2022[291] - The company expects sufficient liquidity to fund operational needs for at least the next 12 months, supported by cash on hand and marketable securities totaling $415.2 million[294] Investments and Growth Strategy - The company aims to expand its test offerings, including advanced NGS tools such as WES and WGS, to drive growth in Advanced Diagnostics[237] - The acquisition of Inivata provided oncology liquid biopsy technology capabilities, enhancing the company's testing services[247] - The Advanced Diagnostics segment supports pharmaceutical firms throughout the drug development process, from discovery to commercialization[248] - The company is committed to leveraging informatics and data-related tools to address real-world problems in oncology[238] - The company plans to invest in information technology and automation to reduce testing costs and improve value[239] - The company remains optimistic about growth opportunities in key markets despite potential inflationary pressures in 2024[299] Marketable Securities and Fair Value - As of December 31, 2023, the total fair value of marketable securities was $72,715,000, down from $174,809,000 as of December 31, 2022[394][395] - The Company reported a total of $55,485,000 in marketable securities with a maturity of one year or less as of December 31, 2023[396] - The Company’s Level 1 financial assets totaled $370,820,000 as of December 31, 2023[397] - The total gross unrealized losses for marketable securities as of December 31, 2023, were $1,486,000[394] Debt and Financing - The company recorded total long-term debt, net, of $538,198 thousand as of December 31, 2023, slightly increasing from $535,322 thousand in 2022[406] - The estimated fair value of the 0.25% Convertible Senior Notes due 2028 was $262.4 million as of December 31, 2023, up from $218.2 million in 2022[406] - The Company completed the sale of $201.3 million of 2025 Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025, resulting in net proceeds of approximately $194.5 million after discounts and expenses[419] - The total long-term debt as of December 31, 2023, amounts to $546.25 million, with $345 million related to the 2028 Convertible Notes and $201.25 million related to the 2025 Convertible Notes[429]

Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights "NeoGenomics' fourth quarter and full year 2023 results ...

ThirdQuarter 2023 Earnings Results 2 This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdictio ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 18% year-over-year, with total revenue reaching $152 million in Q3 2023 [16][33] - Adjusted EBITDA improved by 129% year-over-year to a positive $3 million, marking the fourth consecutive quarter of adjusted EBITDA growth [17][34] - Adjusted gross profit was $67 million, representing a 25% increase over the prior year, with an adjusted gross margin of 44.2%, an improvement of 247 basis points [18][36] Business Line Data and Key Metrics Changes - Clinical Services revenue increased by 20% year-over-year to $128 million, driven by a 7% increase in volume and a 12% increase in revenue per test [41] - Advanced Diagnostics revenue grew by 8% year-over-year, attributed to macroeconomic conditions and a focus on profitability, with adjusted gross profit improving by 32% [42] Market Data and Key Metrics Changes - NGS (Next-Generation Sequencing) revenue grew over 35%, now representing approximately 25% of total clinical revenue, significantly outpacing overall market growth [16][35] - The company is experiencing a shift towards higher complexity tests, contributing to improved revenue per test [33][41] Company Strategy and Development Direction - The company aims to profitably grow its core business, accelerate Advanced Diagnostics, and enhance its people and culture [21] - A key initiative includes moving to a single LIMS system to improve operational efficiencies and reduce costs, with expected benefits starting in 2024 [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and emphasized a strong history of compliance with CAP and CLIA standards [30][31] - The company raised its revenue guidance for the year, now expecting total revenue between $585 million and $592 million, representing 15% to 16% growth [38][39] Other Important Information - The company completed three submissions to MolDX, including an additional breast application, and is focused on expanding its product offerings [19][25] - The company is actively managing cash burn, ending Q3 with cash and marketable securities of $402 million, and has improved cash flow from operations by 66% year-over-year [37] Q&A Session Summary Question: Concerns about labor inflation and cost of goods - Management acknowledged labor inflation concerns but noted that they have not seen a significant impact on hiring due to diverse labor pools in their operational regions [50][62] Question: Insights on revenue cycle management - Management highlighted that revenue cycle management is a multi-year strategy, with significant improvements expected as they focus on higher complexity tests and pricing initiatives [56][151] Question: Timeline for expanded breast MRD submission - Management expects a faster timeline for the expanded breast indication compared to previous submissions, indicating confidence in their approach [85][86] Question: Growth durability for revenue per test - Management indicated that they expect continued growth in revenue per test driven by NGS and revenue cycle management initiatives, with a multi-year opportunity ahead [111][115] Question: Market share capture for RaDaR - Management noted that the market for RaDaR is significantly underpenetrated, providing ample opportunity for growth, although they did not disclose specific market share expectations [134][135]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to (Registrant's telephone number, including area code) Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9490 NeoGenomics Way, Fort Myers, ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NE ...

Financial Data and Key Metrics Changes - First quarter revenue was $137 million, a 17% increase over the prior year, marking the highest revenue growth by quarter since Q2 of 2021 [12][34] - Adjusted EBITDA improved 63% to negative $7 million, highlighting significant improvements driven by higher gross profit and lower operating expenses [18][37] - Adjusted gross margin was 43.5%, an improvement of 670 basis points over the first quarter of last year [18] Business Line Data and Key Metrics Changes - Clinical services revenue increased 16% to $115 million, driven by a 7% increase in volume and higher revenue per test [12][74] - Pharma services revenue increased 22% to $22 million, driven by both price and higher volume in Pharma, as well as strong revenue growth from Informatics [35] - Average revenue per clinical test increased by 8% to $402, representing an improvement for the eighth consecutive quarter [17] Market Data and Key Metrics Changes - The company has a significant share of oncology patient testing volume in the U.S. and one of the largest patient oncology databases [13] - The first quarter was noted for the highest volume of tests per quarter in the history of NeoGenomics, indicating strong market demand [2] Company Strategy and Development Direction - The company aims to profitably grow its core business, accelerate advanced diagnostics, drive value creation, and enhance people and culture over the next 18 to 24 months [31] - The launch of the RaDaR assay for minimal residual disease (MRD) detection is a key strategic initiative, with plans for further indications [32][68] - The company is focused on operational efficiencies and plans to continue investing in the business to capitalize on future growth opportunities [69] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to historical margins by 2026, emphasizing the importance of executing strategic initiatives [7] - The company is optimistic about the growth trajectory, citing strong revenue growth and improved operational performance [20][30] - Management acknowledged potential risks, including supply chain issues, but remains focused on long-term sustainable growth [118] Other Important Information - The company ended the first quarter with cash and marketable securities of $418 million, with a cash burn of $20 million, an improvement of over 40% from Q1 2022 [19] - The company is revising its full-year revenue guidance upward to between $555 million and $565 million, representing 9% to 11% growth [37] Q&A Session Summary Question: What are some of the things that you're watching out for in the guidance? - Management indicated that they are gaining visibility on revenue cycle initiatives and pricing success, contributing to their confidence in the guidance [24] Question: Can you provide more details on the salesforce structure and any major wins? - Management noted that they are winning more accounts than losing, indicating a positive trend in sales performance [48] Question: How do you view the competitive landscape with recent acquisitions in the market? - Management acknowledged competition but expressed confidence in their market position and the growth potential of the MRD market [72] Question: Can you elaborate on the drivers of increased volume that led to the revenue beat? - Management highlighted the impact of new hires with industry experience and improved turnaround times as key factors [110][112] Question: What are the expectations for pricing sustainability moving forward? - Management believes that the pricing improvements are sustainable and that they have under-managed pricing historically [141] Question: How do you plan to enhance your revenue cycle management? - Management is evaluating their current revenue cycle platform and plans to enhance it, with a focus on capital investment in 2024 [121]

2 1st Quarter Clinical Services Revenue per Test • 8th Consecutive Quarter of Revenue per Test Growth • Revenue per Test Increased 8% over Prior Year to $402 • Focused on Higher-Value Tests • Positive Contributions from Strategic Reimbursement Initiatives Q2 Q3 Q4 Q1 • Gross Margin Improved 620 bps, representing the Third Consecutive Quarter of 500 bps+ of Improvement • Revenue: Highest Revenue Growth by Quarter Since Q2 of 2021. Drivers are increases in revenue per test, volume and Pharma Services revenue. ...